Comparison
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 vs 17q12 Recurrent Deletion Syndrome C6011081
Clinical comparison between 3 Methylcrotonyl Coa Carboxylase 1 Deficiency CN028786 and 17q12 Recurrent Deletion Syndrome for differential diagnosis and treatment planning.
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
A metabolic disorder affecting the processing of leucine, an amino acid. Symptoms may include developmental delay, low blood sugar, and feeding problems. Dietary restrictions and supplementation are typically used in management.
17q12 Recurrent Deletion Syndrome C6011081
A genetic condition from deletion on chromosome 17. Can involve developmental delays, neurological features, and potential kidney involvement. Management requires regular monitoring and supportive therapies.
6 comparison axes
Onset
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
0-null
17q12 Recurrent Deletion Syndrome C6011081
0-null
Onset patterns differ
Severity
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
severe
17q12 Recurrent Deletion Syndrome C6011081
moderate
Different severity levels
Chronic
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
Chronic
17q12 Recurrent Deletion Syndrome C6011081
Chronic
Differing course
Communicable
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
No
17q12 Recurrent Deletion Syndrome C6011081
No
Different transmission
Body System
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
metabolic
17q12 Recurrent Deletion Syndrome C6011081
congenital
Same/different system
Category
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
metabolic
17q12 Recurrent Deletion Syndrome C6011081
genetic
Different category
Bottom line
3-methylcrotonyl-coa-carboxylase-1-deficiency-CN028786 and 17q12-recurrent-deletion-syndrome-C6011081 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 | 17q12 Recurrent Deletion Syndrome C6011081 | Discriminating power |
|---|---|---|---|
| Developmental delay | May occur, potentially alongside metabolic illness; it is not definitive alone. | Described as a possible feature of the deletion syndrome. | Low |
| Feeding or glucose problems | Feeding problems and low blood sugar are described. | Not established by the supplied description. | Moderate |
| Kidney or congenital features | Kidney involvement is not described in the source. | Potential kidney involvement and a congenital genetic origin are described. | Moderate |
When to favor each condition
Choose 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 when
Leucine-pathway metabolic abnormality
This pattern better supports evaluation for the metabolic disorder.
Moderate
Hypoglycemia or feeding difficulty
These features match the supplied metabolic description.
Moderate
Discussion of diet or supplements
The source identifies these as typical management approaches, with clinician direction.
Moderate
Choose 17q12 Recurrent Deletion Syndrome C6011081 when
Suspected or confirmed 17q12 deletion
A relevant chromosomal finding supports this syndrome after clinical correlation.
High
Kidney anomaly with developmental concerns
Potential kidney involvement is described for the deletion syndrome.
Moderate
Need for surveillance and support
The source emphasizes monitoring and supportive therapies rather than metabolic diet therapy.
Moderate
How key tests differ
| Test | 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 | 17q12 Recurrent Deletion Syndrome C6011081 | Interpretation |
|---|---|---|---|
| Organic acid or acylcarnitine testing | May suggest abnormal leucine processing; it is not a diagnosis alone. | Not expected to establish the deletion syndrome. | Abnormal metabolic results require specialist confirmation. |
| Chromosomal microarray | Not the primary test implied by the metabolic description. | May identify a recurrent 17q12 deletion. | Genetic results need clinical correlation and do not define severity. |
| Glucose and kidney assessment | Glucose assessment may be relevant when hypoglycemia is suspected. | Kidney evaluation may be relevant because involvement is potential. | Select tests from the presentation; neither result alone proves either condition. |
Prognosis comparison
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
- Outcome
- Long-term outcome is not established; the source labels it severe and chronic.
- Factors
- Glucose stability, feeding problems, metabolic control, and development may influence course.
17q12 Recurrent Deletion Syndrome C6011081
- Outcome
- Outcome is not established; the source labels it moderate and chronic with variable features.
- Factors
- Developmental, neurological, and possible kidney findings may affect outlook.
Time frame: Lifelong follow-up may be relevant, but no precise timeline is established.
Confirmed diagnosis, individual findings, and response to supportive care guide prognosis.
Complications comparison
| Complication | Presentation |
|---|---|
| Metabolic decompensation | A concern given impaired leucine processing and possible hypoglycemia. Not described in the supplied source. Frequency and severity are not established here. |
| Kidney involvement | Not established by the source. Potential and warrants clinician-directed monitoring. Its presence and extent vary and are not quantified. |
| Developmental impact | Developmental delay may occur. Developmental delays and neurological features may occur. Supportive care is individualized; no universal outcome is established. |
Patient education highlights
- HighDifferent causes
One condition affects leucine metabolism; the other results from a chromosome 17 deletion.
- HighLimits of tests
An abnormal laboratory or genetic result needs clinician interpretation and is not a complete care plan.
- MediumCare approach
Metabolic care may include diet and supplements; deletion care emphasizes monitoring and supportive therapy.